Search

Displaying results 4751 - 4760 of 8010 in total
  1. Drug

    NOX-700

    go.drugbank.com/drugs/DB05464
    Experimental

    NOX-700, an new orally active dithiocarbamate-based nitric oxide (NO) blocking agent that is in development for the treatment of diabetes mellitus (type 2 diabetes). … It has since been found that oxidative signaling of the redox-sensitive transcription factor, NF-κB, and inhibiting protein glycation are responsible for the drug's therapeutic effects.

  2. Drug

    Prezatide copper

    go.drugbank.com/drugs/DB14683
    Investigational

    Prezatide is used in cosmetic products for the skin and hair.

  3. Drug

    Pimagedine

    go.drugbank.com/drugs/DB05383
    Investigational

    Pimagedine has been developed by Synvista Therapeutics, Inc for the treatment of diabetic kidney disease. … It is an advanced glycation end product inhibitor which manages diabetic nephropathy, either alone or in combination with other therapies.

  4. Drug

    Etazolate

    go.drugbank.com/drugs/DB05881
    Investigational

    EHT 0202 is developed to treat neurodegenerative disorders by ExonHit Therapeutics.

  5. Drug

    REC-994

    go.drugbank.com/drugs/DB15616
    Investigational

    REC-994 was cleared by the FDA in July, 2018 for a phase I trial for the treatment of cerebral cavernous malformation (CCM).

  6. Drug

    MB07811

    go.drugbank.com/drugs/DB05192
    Investigational

    The combination of selectivity for the beta form of the receptor, liver targeting and other structural characteristics that limit extra-hepatic activity is designed to provide significant efficacy while … MB07811 is the first of a novel class of product candidates discovered by Metabasis designed to lower serum cholesterol and triglycerides.

  7. Drug

    OT-551

    go.drugbank.com/drugs/DB05650
    Investigational

    degeneration (AMD) by protecting against retina photoreceptor cell death and inhibiting angiogenesis, the growth of small blood vessels leading to the wet-form of AMD. … It is intended to treat Age-related macular Degeneration (AMD), and preclinical research results indicate additional uses for OT-551, including treatment of early stage and advanced dry age-related macular

  8. Drug

    SNS-314

    go.drugbank.com/drugs/DB06134
    Investigational

    SNS-314 is a potent and selective inhibitor of Aurora kinases A, B, and C. Proliferating cells treated with SNS-314 bypass the mitotic spindle checkpoint and fail to undergo cytokinesis, leading to multiple rounds of endoreduplication an...

  9. Drug

    Lumefantrine co-artemether

    go.drugbank.com/drugs/DB13085
    ApprovedInvestigationalWithdrawn

    The exact mechanism of action of lumefantrine is not well defined, but it is thought to inhibit -hematin formation, an important detoxification pathway for the parasite. … Lumefantrine Co-Artemether (Riamet) has been investigated for the treatment of Malaria, Malaria, Falciparum, Malaria in Pregnancy, Uncomplicated Malaria, and Uncomplicated Knowlesi Malaria.

  10. Drug

    Metenkefalin

    go.drugbank.com/drugs/DB12668
    Investigational

    [A203210] Metenkefalin, along with [tridecactide], are under investigation as an immunomodulatory therapy for moderate to severe COVID-19.[L13874,L13877]

    Categories: Experimental Unapproved Treatments for COVID-19